Komocsi A, et al. - Researchers, herein, focused on the clinical benefits of selecting P2Y₁₂-inhibitors based on platelet function testing (PFT). It was shown that PFT-guided treatment with a high rate of switch-over to prasugrel was associated with a lower risk for mortality among acute myocardial infarction (AMI) patients. Furthermore, prasugrel was identified as a predictor of lower mortality in patients with high platelet reactivity on clopidogrel, but not in the overall cohort of AMI.